The signalling cascade from initial stimulus to downstream effector — and where therapeutic intervention is possible at each node.
The programmed cell death protein-1 (PD-1) pathway is a critical adaptive immune checkpoint that maintains peripheral tolerance and prevents autoimmunity under physiological conditions. PD-1, expressed on activated T-cells, NK cells, and B-cells, interacts with its ligands PD-L1 (CD274, expressed broadly on tumour cells, stromal cells, and APCs) and PD-L2 (CD273, predominantly on APCs). PD-1 ligation delivers inhibitory signals through recruitment of SHP-2 phosphatase, attenuating T-cell receptor signalling, reducing cytokine production, and inducing a functionally exhausted phenotype — a state characterised by diminished effector function but preserved cell viability.
Tumour cells exploit this physiological checkpoint by upregulating PD-L1 expression — driven by oncogenic signals (KRAS, EGFR mutations), epigenetic mechanisms, and IFN-γ from infiltrating immune cells — to evade cytotoxic T-cell destruction. High tumour mutational burden (TMB) and microsatellite instability-high (MSI-H) status are associated with enhanced neoantigen load and greater PD-1 pathway dependence, predicting responsiveness to checkpoint blockade. Programmed death-ligand 1 expression by immunohistochemistry (CPS or TPS scoring) is used as a predictive biomarker for patient selection in multiple tumour types.
Anti-PD-1 and anti-PD-L1 monoclonal antibodies reinvigorate exhausted tumour-infiltrating lymphocytes, restoring effector function and enabling immune-mediated tumour destruction. Dual checkpoint blockade combining anti-PD-1 with anti-CTLA-4 (ipilimumab) produces synergistic anti-tumour immunity via complementary mechanisms — CTLA-4 blockade acts primarily in lymph nodes to amplify T-cell priming, while PD-1 blockade restores effector function in the tumour microenvironment. This combination has transformed outcomes in advanced melanoma and is established across multiple solid tumour indications.
Upstream blockade vs downstream blockade — understanding the distinction is critical for treatment selection and sequencing.
Clinically actionable insights for treatment selection and sequencing
The programmed cell death protein-1 (PD-1) pathway is a critical adaptive immune checkpoint that maintains peripheral tolerance and prevents autoimmunity under physiological conditions.
PD-1, expressed on activated T-cells, NK cells, and B-cells, interacts with its ligands PD-L1 (CD274, expressed broadly on tumour cells, stromal cells, and APCs) and PD-L2 (CD273, predominantly on APCs).
PD-1 ligation delivers inhibitory signals through recruitment of SHP-2 phosphatase, attenuating T-cell receptor signalling, reducing cytokine production, and inducing a functionally exhausted phenotype — a state characterised by diminished effector function but preserved cell viability.
Tumour cells exploit this physiological checkpoint by upregulating PD-L1 expression — driven by oncogenic signals (KRAS, EGFR mutations), epigenetic mechanisms, and IFN-γ from infiltrating immune cells — to evade cytotoxic T-cell destruction.
Guidelines, trials, clinical briefs, podcasts and CPD connected to this pathway.
Get Men's Health Drug Science updates, related trials and education resources in your ClinicaliQ preferences.
Complete the reflective questions and self-assessment to claim your CPD certificate for this molecular mechanism hub.
Go to CPD Centre →